CORDIS
EU research results

CORDIS

English EN
NMR tools for drug design validated on phosphatases

NMR tools for drug design validated on phosphatases

Objective

In this STREP we intend to use cutting-edge nuclear magnetic resonance (NMR) techniques to develop a fast, integrated approach to support structure-based drug design. The project will speed up drug design efforts for typical drug targets and will shorten t he lead-time for new drugs. We will develop fast, reliable and robust NMR techniques for exact structural and dynamic characterization of drug-receptor interactions at atomic resolution, thus enabling and/or improving the potential for directed development of drugs exhibiting a maximum of desired interaction characteristics in a relatively short time. Protocols for obtaining the NMR data needed for the characterization of proteins, inhibitors and protein-inhibitor complexes will be developed, starting from known X-ray structures, thus establishing a tight connection between NMR and X-ray technology and exploiting optimally the complementary strengths of both techniques. The new NMR technologies will be complemented by computer modelling for protein-inhibito r complexes and by advanced tailored protein expression methods. In order to show the impact for drug development, the new approach will aim at phosphatases, a major class of drug targets with broad medical implications. A majority of cellular functions d epend on phosphorylation by kinases and de-phosphorylation by phosphatases. High eukaryotes encode approximately 500 kinase and 100 phosphatase schemes, corresponding to 3% of the genome. While the importance of kinases in cellular regulation led to substa ntial drug design activities, the importance of phosphatases has only been appreciated recently. Phosphatases regulate insulin signalling, cell growth and the cell cycle. Therefore, the inhibition of phosphatases is perused for the treatment of diabetes, o besity and various cancers. Human genome data provide access to a broad range of phosphatases, allowing systematic drug design using advanced techniques to identify potential inhibitors.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UTRECHT UNIVERSITY, FACULTY OF CHEMISTRY, BIJVOET CENTER FOR BIOMOLECULAR RESEARCH,

Address

Heidelberglaan 8
Utrecht

Netherlands

Administrative Contact

Rolf BOELENS (Prof.)

Participants (5)

Sort alphabetically

Expand all

JOHANN WOLFGANG GOETHE-UNIVERSITY

Germany

CONSORZIO INTERUNIVERSITARIO RISONANZE MAGNETICHE DI METALLPROTEINE PARAMAGNETICHE

Italy

THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL

United Kingdom

SYNTHACON GMBH

Germany

MEDIZINISCHE UNIVERSITÄT WIEN (MEDICAL UNIVERSITY VIENNA)

Austria

Project information

Grant agreement ID: 512077

  • Start date

    1 November 2004

  • End date

    30 April 2008

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 1 120 000

  • EU contribution

    € 1 000 000

Coordinated by:

UTRECHT UNIVERSITY, FACULTY OF CHEMISTRY, BIJVOET CENTER FOR BIOMOLECULAR RESEARCH,

Netherlands